Prof Kim talks to ecancer at ASCO 2025 about data he presented from the phase III OPTIMAL trial.

This demonstrated that DHP107, an oral formulation of paclitaxel, is non-inferior to intravenous paclitaxel in terms of progression-free survival (PFS) for patients with HER2-negative metastatic breast cancer, with a median PFS of 10.02 vs. 8.54 months, and a comparable overall survival of around 33 months.

DHP107 also showed higher response and disease control rates, with fewer instances of peripheral neuropathy, hypersensitivity, and infusion-related reactions, although it was associated with higher rates of neutropenia and mild gastrointestinal side effects.

Overall, DHP107 was found to provide an effective and convenient oral alternative to intravenous paclitaxel with a manageable safety profile, supporting its potential use in routine clinical care.